Recombinant human anti-LK26 antibodies
US5952484A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 5, 1996 |
| Grant date | Sep 14, 1999 |
| Priority date | — |
| Expiry date | Dec 5, 2016 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6833
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.